Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Guided Polarization of iPSC-Derived CD4SP Helper T Cells By CRISPR/Cas9-Based Genome-Editing

Hisashi Yano, MD, Tokuyuki Shinohara, PhD, Keiko Koga, PhD, Shoichi Iriguchi, PhD, Yasuyuki Miyake, Xuewei Song, Megumi Tada, Yoshiaki Kassai, PhD, Hitoshi Kiyoi, MD PhD, Shin Kaneko, MD PhD

Blood (2019) 134 (Supplement_1): 1937.

https://doi.org/10.1182/blood-2019-122193

Published: 2019

Journal Articles

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Eric Robert Fedyk, BSc, MSc, PhD, Neeraja Idamakanti, BVSc MSc DVM, Jia Chen, BSc, MSc, PhD, Jose Estevam, BSc MSc, Vivian Hernandez, BSc PhD, Matthew Wagoner, BSc PhD, Mary Carsillo, BSc DVM PhD, Deborah Berg, RN, MSN, Kristina Allikmets, MD PhD, Gezim Lahu, BSc MSc PhD, Antonio Palumbo, MD

Blood (2019) 134 (Supplement_1): 3136.

https://doi.org/10.1182/blood-2019-128238

Published: 2019

Journal Articles

Informing Clinical Decision and Policy Making in Blood Related Disorders Using Targeted Next Generation Sequencing

Betoul Baz, PhD, Tarek Owaidah, MDFRCPA, Majed Dasouki, MD, Mohammed Abouelhoda, PhD, Dorota Monies, PhD, Nada Al Tassan, PhD

Blood (2019) 134 (Supplement_1): 5776.

https://doi.org/10.1182/blood-2019-122370

Published: 2019

Journal Articles

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Blood (2019) 134 (Supplement_1): 356.

https://doi.org/10.1182/blood-2019-123678

Published: 2019

Journal Articles

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

Scott R Best, BS, Vi Lam, Nur Bruss, BS, Taylor Hashiguchi Rowland, BS, Adam S. Kittai, MD, Tingting Liu, Allison J Berger, PhD, Alexey Danilov, MD PhD

Blood (2019) 134 (Supplement_1): 4313.

https://doi.org/10.1182/blood-2019-123600

Published: 2019

Journal Articles

A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β

Tanabe Mikoto, MD, Nguyen Hoang Maianh, MD, Kohei Hosokawa, MD PhD, Noriharu Nakagawa, MD, Luis Espinoza, MD PhD, Hirohito Yamazaki, MD PhD, Shinji Nakao, MD PhD

Blood (2019) 134 (Supplement_1): 3736.

https://doi.org/10.1182/blood-2019-126677

Published: 2019

Journal Articles

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

Kensuke Matsuda, MD, Yuki Kagoya, MD PhD, Sho Yamazaki, MD PhD, Masashi Miyauchi, MD PhD, Mineo Kurokawa, MD PhD

Blood (2019) 134 (Supplement_1): 1233.

https://doi.org/10.1182/blood-2019-123595

Published: 2019

Journal Articles

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Shanye Yin, PhD, Salma Parvin, PhD, Elisa Ten Hacken, PhD, Rebecca Valentin, MD, Heather Joyal, Laura Z. Rassenti, PhD, Emanuela M. Ghia, PhD, Thomas J. Kipps, MD PhD, Donna S Neuberg, ScD, Lili Wang, MD PhD, Matthew S. Davids, MD, Ruben D. Carrasco, MD PhD, Anthony G. Letai, MD PhD, Catherine J. Wu, MD

Blood (2019) 134 (Supplement_1): 4281.

https://doi.org/10.1182/blood-2019-127293

Published: 2019

Journal Articles

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

Ajai Chari, MD, Dorothy Romanus, RPh, PhD, Aditya Raju, Lauren Cain, Marlo Blazer, PharmD, Eileen Farrelly, Dawn Marie Stull, Sikander Ailawadhi, MD

Blood (2019) 134 (Supplement_1): 1827.

https://doi.org/10.1182/blood-2019-121658

Published: 2019

Journal Articles

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

Eric Robert Fedyk, PhD, Deborah Berg, RN, MSN, Glenda Smithson, PhD, Jose Estevam, Lachy Mclean, MD PhD, Kristina Allikmets, MD PhD, Antonio Palumbo, MD

Blood (2018) 132 (Supplement 1): 3249.

https://doi.org/10.1182/blood-2018-99-112916

Published: 2018

Journal Articles

Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)

Jill A Bell, PhD, Aaron Galaznik, MD, Sharanya Murty, PhD, Megan Pollack, PharmD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 3459.

https://doi.org/10.1182/blood.V130.Suppl_1.3459.3459

Published: 2017

Journal Articles

Low Enrollment of Adult Patients in Clinical Trials: Is Communication Still a Problem?

Alina Basnet, MBBS, Cheryl A Roe, MS, Stephen Graziano, MD, Damare Sherri, MSN, Maria Serrano, BA

Blood (2017) 130 (Supplement 1): 3399.

https://doi.org/10.1182/blood.V130.Suppl_1.3399.3399

Published: 2017

Journal Articles

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Binod Dhakal, MBBS, Ravi Narra, MD, Timothy Smunt, MBA, Angela Canadeo, Pharm D, Saurabh Chhabra, MD, Anita d'Souza, MBBS, MD, Bishal Gyawali, MD PhD, Parameswaran Hari, MD MRCP, MS, Saroj Niraula, MD

Blood (2017) 130 (Supplement 1): 3403.

https://doi.org/10.1182/blood.V130.Suppl_1.3403.3403

Published: 2017

Journal Articles

Real-World Outcomes of Chemoimmunotherapy in Chronic Lymphocytic Leukemia (CLL) Clinical Practice: Results from a Decade of Practice in Helsinki 2005-2015

Vesa Lindström, MD, Tiina M Jarvinen, Juha Mehtälä, Houssem Khanfir, Rosa Juuti, Amy Leval, PhD, Marjaana Säily, MD PhD

Blood (2017) 130 (Supplement 1): 5663.

https://doi.org/10.1182/blood.V130.Suppl_1.5663.5663

Published: 2017

Journal Articles

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Sikander Ailawadhi, Maral DerSarkissian, PhD, Mei Sheng Duh, MPH, ScD, Marie-Hélène Lafeuille, MA, George Posner, BA, Stephen Ralston, PhD, Erin Zagadailov, PharmD, MS, Abbie Ba-Mancini, MSc, MBA, Robert M Rifkin, MD

Blood (2017) 130 (Supplement 1): 5599.

https://doi.org/10.1182/blood.V130.Suppl_1.5599.5599

Published: 2017

Journal Articles

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Jill A Bell, PhD, Aaron Galaznik, MD, Eileen Farrelly, MPH, Sharanya Murty, PhD, Augustina Ogbonnaya, MPH, Michael T. Eaddy, PharmD, PhD, Robert J. Fram, MD, Douglas V. Faller, MD PhD, Vamsi Kota, MBBS

Blood (2017) 130 (Supplement 1): 2167.

https://doi.org/10.1182/blood.V130.Suppl_1.2167.2167

Published: 2017

Journal Articles

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Aaron Galaznik, MD, Jill A Bell, PhD, Laurie Hamilton, MS, Augustina Ogbonnaya, MPH, Kristin Hennenfent, PharmD, Michael T. Eaddy, PharmD, PhD, Yaping Shou, MD PhD

Blood (2017) 130 (Supplement 1): 2183.

https://doi.org/10.1182/blood.V130.Suppl_1.2183.2183

Published: 2017

Journal Articles

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Arko Das, MS, Krishna K Tiwari, BT, Vishwas Joseph, MS, Subrat Mohapatra, MS, Neelesh Lunkad, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3907.

https://doi.org/10.1182/blood.V130.Suppl_1.3907.3907

Published: 2017

Journal Articles

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Leylah M. Drusbosky, PhD, Robinson Vidva, BT, Saji Gera, MT, Anjanasree V. Lakshminarayana, BE, Vijayashree P. Shyamasundar, MS, Ashish Kumar Agrawal, BS, Anay Talawdekar, MT, Taher Abbasi, MS, MBA, Shireen Vali, PhD, Cristina E. Tognon, PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Brian J. Druker, MD, Christopher R. Cogle, MD

Blood (2017) 130 (Supplement 1): 3908.

https://doi.org/10.1182/blood.V130.Suppl_1.3908.3908

Published: 2017

Journal Articles

Driver Mutation in Waldenstrom's Macroglobullinemia and Their Clonal Heterogeneity during Progression and Relapse

Jihye Park, PhD, Antonio Sacco, BS, RN, Salomon Manier, MD, Karma Salem, MD, Mira Mashood, MD, Adriana Perilla-Glen, MBA, Yosra Aljawai, Jiantao Shi, PhD, Eliezer Van Allen, MD, Marzia Capelletti, PhD MMSc, Irene M. Ghobrial, MD, Aldo M. Roccaro, MD PhD

Blood (2016) 128 (22): 1092.

https://doi.org/10.1182/blood.V128.22.1092.1092

Published: 2016

NARROW

Guided Polarization of iPSC-Derived CD4SP Helper T Cells By CRISPR/Cas9-Based Genome-Editing

The Binding of CD38 Therapeutics to Red Blood Cells and Platelets Subverts Depletion of Target Cells

Informing Clinical Decision and Policy Making in Blood Related Disorders Using Targeted Next Generation Sequencing

Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

Neddylation Pathway Regulates Treg Differentiation and T Cell Function in Chronic Lymphocytic Leukemia (CLL) Ex Vivo and Murine In Vivo Studies

A GPI-Anchored Protein, CD109, Protects Hematopoietic Progenitor Cells from Erythroid Differentiation Induced By TGF-β

Synthetic Lethality-Based Approach Identified EED and BRD4 As Critical Survival Factorsin Acte Myeloid Leukemia with Monosomy 7

Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL

Comparative Effectiveness of Triplets Containing Bortezomib (V), Carfilzomib (K), or Ixazomib (I) Combined with a Lenalidomide and Dexamethasone Backbone (Rd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) in Routine Care in the United States (US)

A Single Administration of the Cytolytic CD38 Antibody TAK-079 to Healthy Subjects: Tolerability, Pharmacokinetics and Pharmacodynamics

Healthcare Costs in Elderly Patients with Acute Myeloid Leukemia (AML) in Routine Clinical Care in the United States (US)

Low Enrollment of Adult Patients in Clinical Trials: Is Communication Still a Problem?

Incremental Financial and Health-Related Burden of Novel Drugs Used in the Treatment of Relapsed and/or Refractory Multiple Myeloma (RRMM): A Meta-Analysis of Phase III Randomized Controlled Trials (RCTs)

Real-World Outcomes of Chemoimmunotherapy in Chronic Lymphocytic Leukemia (CLL) Clinical Practice: Results from a Decade of Practice in Helsinki 2005-2015

Cost Offsets in the Treatment Journeys of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Treatment Characteristics and Outcomes for Newly Diagnosed Elderly Patients with Acute Myeloid Leukemia (AML) Treated in the United States with Either 7+3 or a Hypomethylating Agent (HMA)

Healthcare Burden of Patients with Follicular Lymphoma (FL) in Routine Clinical Care in the United States

Predicting Response to IDH1/IDH2 Inhibitors Beyond IDH Mutations Using a Computational Model and Its Validation: A Beat AML Project Study

Predicting Response to BET Inhibitors Using a Computational Model and Its Validation: A Beat AML Project Study

Driver Mutation in Waldenstrom's Macroglobullinemia and Their Clonal Heterogeneity during Progression and Relapse

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only